|
| 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Basic information |
Product Name: | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester | Synonyms: | 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester;Methyl 2-(1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-1H-benzo[d]imidazole-5-carboxylate;methyl 2-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-1H-benzo[d]imidazole-6-carboxylate;Methyl 2-(1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl)-1H-benzo[d]imidazole-6-carboxylate;R-10015,inhibit,R10015,Inhibitor,LIMKs,Reverse Transcriptase,LIM Kinase (LIMK),R 10015 | CAS: | 2097938-51-5 | MF: | C20H19ClN6O2 | MW: | 410.86 | EINECS: | | Product Categories: | | Mol File: | 2097938-51-5.mol | ![1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Structure](CAS/20200331/GIF/2097938-51-5.gif) |
| 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Chemical Properties |
density | 1.465±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO : 62.5 mg/mL (152.12 mM; Need ultrasonic) | form | Solid | pka | 10.68±0.10(Predicted) | color | Off-white to pink |
| 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Usage And Synthesis |
Biological Activity | R-10015 is a potent and selective LIM domain kinase (LIMK) inhibitor with IC50 of 38 nM for human LIMK1. It binds to the ATP-binding pocket and acts as a broad-spectrum antiviral compound for HIV infection. | in vitro | R-10015 (100 μM; 0-4 hours) inhibits cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells. R-10015 inhibits HIV-1 DNA synthesis, nuclear migration, and virion release. R-10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1) .< br/> Western Blot Analysis Cell Line: | CEM-SS T cells | Concentration: | 100 μM | Incubation Time: | 0 hour,0.5 hour,1 hour,2 hours,4 hours | < td class="col1"> Result: Inhibited cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells. | | in vivo | R-10015 (10 mg/kg; ip) displays no indication of toxicity. The result suggests the possibility of short-term use of LIMK inhibitors to block viral infections. < p> Animal Model: | 6-8 weeks female C3H/HeN mice | Dosage: | 10 mg/kg | Administration: | Intraperitoneal injection | Result: | Displayed none indication of toxicity. | < /tr> | target | Target | Value | hLIMK1 (Cell-free assay) | 38 nM |
|
| 1H-Benzimidazole-6-carboxylic acid, 2-[1-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4-piperidinyl]-, methyl ester Preparation Products And Raw materials |
|